COMPARISON OF EFFICACY AND TOLERABILITY OF FULVESTRANT+PLACEBO VS FULVESTRANT+PALBOCICLIB AS FIRST LINE THERAPY FOR POSTMENOPAUSAL WOMEN WITH HR+ METASTATIC BC TREATED WITH 5 YEARS OF HORMONAL THERAPY REMAINING DISEASE FREE MORE THAN 12 MONTHS AFTER COMPLETION OR HAVE DE NOVO METASTATIC DISEASE: